array(40) {
  [0]=>
  string(4) "2165"
  ["article_id"]=>
  string(4) "2165"
  [1]=>
  string(63) "Boston Scientific receives FDA approval for aortic valve system"
  ["article_title"]=>
  string(63) "Boston Scientific receives FDA approval for aortic valve system"
  [2]=>
  string(119) "Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge Aortic Valve System."
  ["short_description"]=>
  string(119) "Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge Aortic Valve System."
  [3]=>
  string(119) "Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge Aortic Valve System."
  ["description"]=>
  string(119) "Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge Aortic Valve System."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(102) "https://www.medicalplasticsnews.com/news/boston-scientific-receives-fda-approval-for-aortic-valve-sys/"
  ["blog_url"]=>
  string(102) "https://www.medicalplasticsnews.com/news/boston-scientific-receives-fda-approval-for-aortic-valve-sys/"
  [15]=>
  string(19) "2019-04-26 23:48:02"
  ["add_date"]=>
  string(19) "2019-04-26 23:48:02"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:40"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2423"
  ["article_id"]=>
  string(4) "2423"
  [1]=>
  string(42) "Hired and Retired: Investing in experience"
  ["article_title"]=>
  string(42) "Hired and Retired: Investing in experience"
  [2]=>
  string(126) "Biotechs continue to pull experienced individuals from larger pharma companies to help progress candidates through the clinic."
  ["short_description"]=>
  string(126) "Biotechs continue to pull experienced individuals from larger pharma companies to help progress candidates through the clinic."
  [3]=>
  string(126) "Biotechs continue to pull experienced individuals from larger pharma companies to help progress candidates through the clinic."
  ["description"]=>
  string(126) "Biotechs continue to pull experienced individuals from larger pharma companies to help progress candidates through the clinic."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(147) "https://www.biopharma-reporter.com/Article/2019/04/26/Hired-and-Retired-Investing-in-experience?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(147) "https://www.biopharma-reporter.com/Article/2019/04/26/Hired-and-Retired-Investing-in-experience?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-04-26 23:20:00"
  ["add_date"]=>
  string(19) "2019-04-26 23:20:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:36"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2166"
  ["article_id"]=>
  string(4) "2166"
  [1]=>
  string(37) "Sling The Mesh announce protest plans"
  ["article_title"]=>
  string(37) "Sling The Mesh announce protest plans"
  [2]=>
  string(135) "Campaign group Sling The Mesh to protest against new health guidelines they believe pave the way for generations of women to be harmed."
  ["short_description"]=>
  string(135) "Campaign group Sling The Mesh to protest against new health guidelines they believe pave the way for generations of women to be harmed."
  [3]=>
  string(135) "Campaign group Sling The Mesh to protest against new health guidelines they believe pave the way for generations of women to be harmed."
  ["description"]=>
  string(135) "Campaign group Sling The Mesh to protest against new health guidelines they believe pave the way for generations of women to be harmed."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(79) "https://www.medicalplasticsnews.com/news/sling-the-mesh-announce-protest-plans/"
  ["blog_url"]=>
  string(79) "https://www.medicalplasticsnews.com/news/sling-the-mesh-announce-protest-plans/"
  [15]=>
  string(19) "2019-04-26 23:00:59"
  ["add_date"]=>
  string(19) "2019-04-26 23:00:59"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:40"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1970"
  ["article_id"]=>
  string(4) "1970"
  [1]=>
  string(63) "How to demonstrate empathy and compassion in a pharmacy setting"
  ["article_title"]=>
  string(63) "How to demonstrate empathy and compassion in a pharmacy setting"
  [2]=>
  string(150) "Showing kindness and compassion is central to the delivery of patient-centred care and can help make better use of the short time pharmacists have in "
  ["short_description"]=>
  string(150) "Showing kindness and compassion is central to the delivery of patient-centred care and can help make better use of the short time pharmacists have in "
  [3]=>
  string(164) "Showing kindness and compassion is central to the delivery of patient-centred care and can help make better use of the short time pharmacists have in consultations."
  ["description"]=>
  string(164) "Showing kindness and compassion is central to the delivery of patient-centred care and can help make better use of the short time pharmacists have in consultations."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(145) "https://www.pharmaceutical-journal.com/learning/learning-article/how-to-demonstrate-empathy-and-compassion-in-a-pharmacy-setting/20206124.article"
  ["blog_url"]=>
  string(145) "https://www.pharmaceutical-journal.com/learning/learning-article/how-to-demonstrate-empathy-and-compassion-in-a-pharmacy-setting/20206124.article"
  [15]=>
  string(19) "2019-04-26 18:38:00"
  ["add_date"]=>
  string(19) "2019-04-26 18:38:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:55"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:55"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2184"
  ["article_id"]=>
  string(4) "2184"
  [1]=>
  string(65) "WHO prequalification for rituximab and trastuzumab: first results"
  ["article_title"]=>
  string(65) "WHO prequalification for rituximab and trastuzumab: first results"
  [2]=>
  string(150) "At the 17th Biosimilar Medicines Conference, the World Health Organization (WHO) outlined the first results for their pilot project for the prequalifi"
  ["short_description"]=>
  string(150) "At the 17th Biosimilar Medicines Conference, the World Health Organization (WHO) outlined the first results for their pilot project for the prequalifi"
  [3]=>
  string(195) "
At the 17th Biosimilar Medicines Conference, the World Health Organization (WHO) outlined the first results for their pilot project for the prequalification of two cancer drug biosimilars.
"
  ["description"]=>
  string(195) "
At the 17th Biosimilar Medicines Conference, the World Health Organization (WHO) outlined the first results for their pilot project for the prequalification of two cancer drug biosimilars.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(99) "http://www.gabionline.net//Reports/WHO-prequalification-for-rituximab-and-trastuzumab-first-results"
  ["blog_url"]=>
  string(99) "http://www.gabionline.net//Reports/WHO-prequalification-for-rituximab-and-trastuzumab-first-results"
  [15]=>
  string(19) "2019-04-26 17:15:14"
  ["add_date"]=>
  string(19) "2019-04-26 17:15:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:40"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2185"
  ["article_id"]=>
  string(4) "2185"
  [1]=>
  string(57) "Health Canada announces naming convention for biologicals"
  ["article_title"]=>
  string(57) "Health Canada announces naming convention for biologicals"
  [2]=>
  string(150) "Following a number of stakeholder consultations including the 2018 Consultation on the Naming of Biologic Drugs [1], Health Canada has decided that bi"
  ["short_description"]=>
  string(150) "Following a number of stakeholder consultations including the 2018 Consultation on the Naming of Biologic Drugs [1], Health Canada has decided that bi"
  [3]=>
  string(566) "
Following a number of stakeholder consultations including the 2018 Consultation on the Naming of Biologic Drugs [1], Health Canada has decided that biological drugs, including biosimilars, will be identified by their unique brand name and non-proprietary (common) name, without the addition of a product-specific suffix. Under this naming convention, both the brand name and non-proprietary name should be used throughout the medication use process so that biologicals that share the same non-proprietary name can be distinguished by their unique brand names.
"
  ["description"]=>
  string(566) "
Following a number of stakeholder consultations including the 2018 Consultation on the Naming of Biologic Drugs [1], Health Canada has decided that biological drugs, including biosimilars, will be identified by their unique brand name and non-proprietary (common) name, without the addition of a product-specific suffix. Under this naming convention, both the brand name and non-proprietary name should be used throughout the medication use process so that biologicals that share the same non-proprietary name can be distinguished by their unique brand names.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(105) "http://www.gabionline.net//Policies-Legislation/Health-Canada-announces-naming-convention-for-biologicals"
  ["blog_url"]=>
  string(105) "http://www.gabionline.net//Policies-Legislation/Health-Canada-announces-naming-convention-for-biologicals"
  [15]=>
  string(19) "2019-04-26 17:09:24"
  ["add_date"]=>
  string(19) "2019-04-26 17:09:24"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:40"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1989"
  ["article_id"]=>
  string(4) "1989"
  [1]=>
  string(167) "New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)"
  ["article_title"]=>
  string(167) "New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)"
  [2]=>
  string(150) "DUBLIN--(BUSINESS WIRE)--Apr. 26, 2019-- Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial "
  ["short_description"]=>
  string(150) "DUBLIN--(BUSINESS WIRE)--Apr. 26, 2019-- Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial "
  [3]=>
  string(249) "DUBLIN--(BUSINESS WIRE)--Apr. 26, 2019-- Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for the treatment of active thyroid..."
  ["description"]=>
  string(249) "DUBLIN--(BUSINESS WIRE)--Apr. 26, 2019-- Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for the treatment of active thyroid..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/new-data-phase-3-teprotumumab-trial-optic-shows-dramatic-reduction-proptosis-eye-bulging-main-cause-18136.html?utm_source=ddc&utm_medium=rss&utm_campaign=New+Data+from+Phase+3+Teprotumumab+Trial+%28OPTIC%29+Shows+Dramatic+Reduction+in+Proptosis%2C+or+Eye+Bulging"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/new-data-phase-3-teprotumumab-trial-optic-shows-dramatic-reduction-proptosis-eye-bulging-main-cause-18136.html?utm_source=ddc&utm_medium=rss&utm_campaign=New+Data+from+Phase+3+Teprotumumab+Trial+%28OPTIC%29+Shows+Dramatic+Reduction+in+Proptosis%2C+or+Eye+Bulging"
  [15]=>
  string(19) "2019-04-26 15:05:05"
  ["add_date"]=>
  string(19) "2019-04-26 15:05:05"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5912"
  ["article_id"]=>
  string(4) "5912"
  [1]=>
  string(54) "2nd Middle East Pharmacy and Pharmaceutical Conference"
  ["article_title"]=>
  string(54) "2nd Middle East Pharmacy and Pharmaceutical Conference"
  [2]=>
  string(150) "ME Conferences welcomes you at Pharma Conference 2019  going to be held in Dubai, UAE during December 09-10, 2019 which unites brief keynote presentat"
  ["short_description"]=>
  string(150) "ME Conferences welcomes you at Pharma Conference 2019  going to be held in Dubai, UAE during December 09-10, 2019 which unites brief keynote presentat"
  [3]=>
  string(500) "ME Conferences welcomes you at Pharma Conference 2019  going to be held in Dubai, UAE during December 09-10, 2019 which unites brief keynote presentations, speaker talks, exhibitions, Symposiums, workshops. Pharma Conference 2019 is the Pharma meetings which will be most visited by all the eminent speakers, educators, postgraduates, affiliations, business meanders under a solitary rooftop. This Pharma conference 2019 will assist to framework organization, B2B teaming up amidst specialists and..."
  ["description"]=>
  string(500) "ME Conferences welcomes you at Pharma Conference 2019  going to be held in Dubai, UAE during December 09-10, 2019 which unites brief keynote presentations, speaker talks, exhibitions, Symposiums, workshops. Pharma Conference 2019 is the Pharma meetings which will be most visited by all the eminent speakers, educators, postgraduates, affiliations, business meanders under a solitary rooftop. This Pharma conference 2019 will assist to framework organization, B2B teaming up amidst specialists and..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(88) "https://www.pharmiweb.com/event/2nd-middle-east-pharmacy-and-pharmaceutical-conference-1"
  ["blog_url"]=>
  string(88) "https://www.pharmiweb.com/event/2nd-middle-east-pharmacy-and-pharmaceutical-conference-1"
  [15]=>
  string(19) "2019-04-26 13:22:23"
  ["add_date"]=>
  string(19) "2019-04-26 13:22:23"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-11 12:49:42"
  ["create_at"]=>
  string(19) "2019-11-11 12:49:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1990"
  ["article_id"]=>
  string(4) "1990"
  [1]=>
  string(142) "Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)"
  ["article_title"]=>
  string(142) "Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)"
  [2]=>
  string(150) "FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 25, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, doub"
  ["short_description"]=>
  string(150) "FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 25, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, doub"
  [3]=>
  string(241) "FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 25, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an..."
  ["description"]=>
  string(241) "FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 25, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/gilead-announces-topline-data-phase-3-stellar-3-study-selonsertib-bridging-fibrosis-f3-due-18130.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+Announces+Topline+Data+From+Phase+3+STELLAR-3+Study+of+Selonsertib+in+Bridging+Fibrosis+%28F3%29+Due+to+Nonalc"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/gilead-announces-topline-data-phase-3-stellar-3-study-selonsertib-bridging-fibrosis-f3-due-18130.html?utm_source=ddc&utm_medium=rss&utm_campaign=Gilead+Announces+Topline+Data+From+Phase+3+STELLAR-3+Study+of+Selonsertib+in+Bridging+Fibrosis+%28F3%29+Due+to+Nonalc"
  [15]=>
  string(19) "2019-04-26 07:05:20"
  ["add_date"]=>
  string(19) "2019-04-26 07:05:20"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1991"
  ["article_id"]=>
  string(4) "1991"
  [1]=>
  string(108) "Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market"
  ["article_title"]=>
  string(108) "Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market"
  [2]=>
  string(150) "INDIANAPOLIS, April 25, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the company has been working to facilitate the wit"
  ["short_description"]=>
  string(150) "INDIANAPOLIS, April 25, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the company has been working to facilitate the wit"
  [3]=>
  string(251) "INDIANAPOLIS, April 25, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the company has been working to facilitate the withdrawal of Lartruvo (olaratumab) from the market for the treatment of advanced soft tissue sarcoma..."
  ["description"]=>
  string(251) "INDIANAPOLIS, April 25, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the company has been working to facilitate the withdrawal of Lartruvo (olaratumab) from the market for the treatment of advanced soft tissue sarcoma..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(281) "https://www.drugs.com/clinical_trials/lilly-establish-access-program-patients-prepares-withdraw-lartruvo-global-market-18131.html?utm_source=ddc&utm_medium=rss&utm_campaign=Lilly+to+Establish+an+Access+Program+for+Patients+as+it+Prepares+to+Withdraw+Lartruvo+from+the+Global+Market"
  ["blog_url"]=>
  string(281) "https://www.drugs.com/clinical_trials/lilly-establish-access-program-patients-prepares-withdraw-lartruvo-global-market-18131.html?utm_source=ddc&utm_medium=rss&utm_campaign=Lilly+to+Establish+an+Access+Program+for+Patients+as+it+Prepares+to+Withdraw+Lartruvo+from+the+Global+Market"
  [15]=>
  string(19) "2019-04-26 07:04:33"
  ["add_date"]=>
  string(19) "2019-04-26 07:04:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2215"
  ["article_id"]=>
  string(4) "2215"
  [1]=>
  string(66) "How to Use Scientific Method to Transform Your Recruiting Programs"
  ["article_title"]=>
  string(66) "How to Use Scientific Method to Transform Your Recruiting Programs"
  [2]=>
  string(158) "Many think that we are in the beginning of a new “golden” era of science. As evidenced by the huge popularity of TED talks, academics in podcasts,"
  ["short_description"]=>
  string(158) "Many think that we are in the beginning of a new “golden” era of science. As evidenced by the huge popularity of TED talks, academics in podcasts,"
  [3]=>
  string(689) "
Many think that we are in the beginning of a new “golden” era of science. As evidenced by the huge popularity of TED talks, academics in podcasts, and increase of book sales by scientists, science has again become cool. Bridging the gap between ideas or new discoveries and practical application to our own work environments […]
&#nl
The post How to Use Scientific Method to Transform Your Recruiting Programs appeared first on ERE Media.
&#nl"
  ["description"]=>
  string(689) "
Many think that we are in the beginning of a new “golden” era of science. As evidenced by the huge popularity of TED talks, academics in podcasts, and increase of book sales by scientists, science has again become cool. Bridging the gap between ideas or new discoveries and practical application to our own work environments […]
&#nl
The post How to Use Scientific Method to Transform Your Recruiting Programs appeared first on ERE Media.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "2"
  ["category"]=>
  string(1) "2"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "51"
  ["rss_id"]=>
  string(2) "51"
  [14]=>
  string(101) "https://www.eremedia.com/webinars/how-to-use-scientific-method-to-transform-your-recruiting-programs/"
  ["blog_url"]=>
  string(101) "https://www.eremedia.com/webinars/how-to-use-scientific-method-to-transform-your-recruiting-programs/"
  [15]=>
  string(19) "2019-04-26 06:54:56"
  ["add_date"]=>
  string(19) "2019-04-26 06:54:56"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:45"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1926"
  ["article_id"]=>
  string(4) "1926"
  [1]=>
  string(111) "FDA Approves Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis In Adults"
  ["article_title"]=>
  string(111) "FDA Approves Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis In Adults"
  [2]=>
  string(150) "LAVAL, Quebec, April 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of t"
  ["short_description"]=>
  string(150) "LAVAL, Quebec, April 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of t"
  [3]=>
  string(251) "LAVAL, Quebec, April 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced today that the U.S. Food and..."
  ["description"]=>
  string(251) "LAVAL, Quebec, April 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced today that the U.S. Food and..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-duobrii-halobetasol-propionate-tazarotene-lotion-0-01-0-045-plaque-psoriasis-adults-4953.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Duobrii+%28halobetasol+propionate+and+tazarotene%29+Lotion+0.01%25%2F0.045%25+for+Plaque+Psoriasis+In+Adul"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-duobrii-halobetasol-propionate-tazarotene-lotion-0-01-0-045-plaque-psoriasis-adults-4953.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Duobrii+%28halobetasol+propionate+and+tazarotene%29+Lotion+0.01%25%2F0.045%25+for+Plaque+Psoriasis+In+Adul"
  [15]=>
  string(19) "2019-04-26 05:04:03"
  ["add_date"]=>
  string(19) "2019-04-26 05:04:03"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}